Home Cart Sign in  
Chemical Structure| 65646-68-6 Chemical Structure| 65646-68-6

Structure of 65646-68-6

Chemical Structure| 65646-68-6

*Storage: {[sel_prStorage]}

*Shipping: {[sel_prShipping]}

,{[proInfo.pro_purity]}

Fenretinide, the deriverative of retinoid, can bind to retinoic acid receptors (RAR) and induce cell death.

Synonyms: 4-HPR; Fenretinide; HPR

4.5 *For Research Use Only !

{[proInfo.pro_purity]}
Cat. No.: {[proInfo.prAm]} Purity: {[proInfo.pro_purity]}

Change View

Size Price VIP Price

US Stock

Global Stock

In Stock
{[ item.pr_size ]} Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]}

US Stock: ship in 0-1 business day
Global Stock: ship in 5-7 days

  • {[ item.pr_size ]}

In Stock

- +

Please Login or Create an Account to: See VIP prices and availability

US Stock: ship in 0-1 business day
Global Stock: ship in 2 weeks

  • 1-2 Day Shipping
  • High Quality
  • Technical Support
Product Citations

Alternative Products

Product Details of all-trans-N-(4-Hydroxyphenyl)retinamide

CAS No. :65646-68-6
Formula : C26H33NO2
M.W : 391.55
SMILES Code : CC1=C(C(C)(CCC1)C)/C=C/C(C)=C/C=C/C(C)=C/C(NC2=CC=C(C=C2)O)=O
Synonyms :
4-HPR; Fenretinide; HPR
MDL No. :MFCD00792674
InChI Key :AKJHMTWEGVYYSE-FXILSDISSA-N
Pubchem ID :5288209

Safety of all-trans-N-(4-Hydroxyphenyl)retinamide

GHS Pictogram:
Signal Word:Warning
Hazard Statements:H302+H312+H332-H315-H319-H335
Precautionary Statements:P261-P280-P305+P351+P338

Isoform Comparison

Biological Activity

In Vitro:

Cell Line
Concentration Treated Time Description References
TUBO cells 5µM to 100µM 72 h To evaluate the effect of Bio-nFeR on TUBO cell viability, showing a dose-dependent inhibition of cell viability. PMC11536529
MDA-MB-231 cells 5µM to 100µM 72 h To evaluate the effect of Bio-nFeR on MDA-MB-231 cell viability, showing a dose-dependent inhibition of cell viability. PMC11536529
MCF7 cells 5µM to 100µM 72 h To evaluate the effect of Bio-nFeR on MCF7 cell viability, showing a dose-dependent inhibition of cell viability. PMC11536529
RAW 264.7 cells 0.1, 1, 10 μM Fenretinide dose-dependently reduced M1 polarization in LOP-treated RAW 264.7 cells and decreased mRNA expression of M1 markers (iNos and Cox2) and pro-inflammatory cytokines (Tnfa and Il1b). PMC9939369
Rh30 cells 4 μM 48 h To investigate the mechanism of Fenretinide-induced cell death, results showed that Fenretinide induces cell death through ROS production and cytoplasmic vacuolization PMC7370225
Rh4 cells 3 μM 48 h To investigate the mechanism of Fenretinide-induced cell death, results showed that Fenretinide induces cell death through ROS production and cytoplasmic vacuolization PMC7370225
Human airway smooth-muscle cells 5 μM 5 h To evaluate the effects of Fenretinide on sphingolipid metabolites in airway smooth-muscle cells. Results showed that Fenretinide increased sphinganine and dihydroceramides, and decreased intracellular calcium concentration. PMC7605160
Human lung alveolar epithelial cell line A549 5 μM 5 h To evaluate the effects of Fenretinide on sphingolipid metabolites in lung cells. Results showed that Fenretinide increased sphinganine and dihydroceramides. PMC7605160
Rat lung goblet cell line 1.25 µM Selectively prevents MUC5AC overexpression without significantly affecting MUC5B expression PMC11105061
CFBE 41o- cells 1.25 µM Selectively prevents MUC5AC overexpression without significantly affecting MUC5B expression PMC11105061
MCF7 cells 5 μM 4 h Evaluate the effect of Fenretinide on CERK activity, found it suppresses NBD-C6-C1P production PMC11326893

In Vivo:

Species
Animal Model
Administration Dosage Frequency Description References
129 Sv mice HER2/neu transgenic mouse model Oral gavage 100 mg/kg 5 days/week, from week 14 to week 32 post-birth To evaluate the effect of Bio-nFeR on mammary tumorigenesis and metastasis in HER2/neu transgenic mice, showing significant inhibition of tumor occurrence and metastasis. PMC11536529
Mice CFTR knockout mice Not mentioned 5–10 mg/kg Not mentioned Corrects pro-inflammatory lipid imbalance by decreasing AA levels and upregulating DHA levels PMC11105061
Sprague-Dawley rats Subcutaneous implantation model Subcutaneous injection 5% w/w 1 month Evaluate the in vivo release properties of PLGA-PVP-4HPR implants, showing that TEAC-PVP-4HPR PLGA implants achieved nearly complete release of 4HPR over 1 month PMC7522920

Clinical Trial:

NCT Number Conditions Phases Recruitment Completion Date Locations
NCT02495415 Peripheral T-cell Lymphoma PHASE2 UNKNOWN 2025-12-21 Banner MD Anderson Cancer Cent... More >>er, Gilbert, Arizona, 85234, United States|USC Norris Comprehensive Cancer Center, Los Angeles, California, 90033, United States|University of California, Los Angeles, Los Angeles, California, 90095, United States|Emory University, Atlanta, Georgia, 30322, United States|University of Kansas Cancer Center, Westwood, Kansas, 66205, United States|Norton Healthcare, Louisville, Kentucky, 40202, United States|University of Louisville, Louisville, Kentucky, 40202, United States|Hackensack University Medical Center, Hackensack, New Jersey, 07601, United States|Bon Secours Saint Francis Cancer Center, Greenville, South Carolina, 29607, United States|Baylor University Medical Center, Dallas, Texas, 75246, United States|University of Texas, Southwestern, Dallas, Texas, 75390, United States Less <<
NCT04234048 T-cell Lymphoma|Cutaneous/Peri... More >>pheral T-Cell Lymphoma|Peripheral T-cell Lymphoma|Peripheral T-Cell Lymphoma, Not Classified|Primary Cutaneous T-cell Lymphoma|Cutaneous T-Cell Lymphoma, Unspecified|Cutaneous T-cell Lymphoma|Follicular T-Cell Lymphoma|Angioimmunoblastic T-cell Lymphoma|Sézary's Disease|Mycosis Fungoides Less << PHASE1 RECRUITING 2025-11-25 Mayo Clinic Arizona, Scottsdal... More >>e, Arizona, 85259, United States|City of Hope Medical Foundation, Duarte, California, 91010, United States|University of Southern California, Los Angeles, California, 90007, United States|University of Colorado Anschutz Medical Campus, Aurora, Colorado, 80045, United States|University of Michigan, Ann Arbor, Michigan, 48109, United States|Barbara Ann Karmanos Cancer Institute Wayne State University, Detroit, Michigan, 48201, United States|Columbia University, New York, New York, 10032, United States|University of Pittsburgh Medical Center (UPMC), Pittsburgh, Pennsylvania, 15219, United States|The University of Texas MD Anderson Cancer Center, Houston, Texas, 77030, United States Less <<
NCT00006471 Head and Neck Cancer PHASE2 COMPLETED 2025-07-04 University of Texas - MD Ander... More >>son Cancer Center, Houston, Texas, 77030-4009, United States Less <<
NCT00429936 Geographic Atrophy|Dry Age Rel... More >>ated Macular Degeneration Less << PHASE2 COMPLETED 2025-05-10 -

Protocol

Bio Calculators
Preparing Stock Solutions 1mg 5mg 10mg

1 mM

5 mM

10 mM

2.55mL

0.51mL

0.26mL

12.77mL

2.55mL

1.28mL

25.54mL

5.11mL

2.55mL

Dissolving Methods
Please choose the appropriate dissolution scheme according to your animal administration guide.For the following dissolution schemes, clear stock solution should be prepared according to in vitro experiments, and then cosolvent should be added in turn:

in order to ensure the reliability of the experimental results, the clarified stock solution can be properly preserved according to the storage conditions; The working fluid for in vivo experiment is recommended to be prepared now and used on the same day;

The percentage shown in front of the following solvent refers to the volume ratio of the solvent in the final solution; If precipitation or precipitation occurs in the preparation process, it can be assisted by heating and/or ultrasound.
Protocol 1
Protocol 2

References

 

Historical Records

Categories